Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia-Reference-Cited by-同舟云学术

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

Published:2020-12 Issue: Volume:Volume 16 Page:3197-3208
ISSN:1178-2021
Container-title:Neuropsychiatric Disease and Treatment
language:en
Short-container-title:NDT

Author:

Lambert Martin,Sanchez Pedro^ORCID,Bergmans Paul,Gopal Srihari^ORCID,Mathews Maju,Wooller Annette,Pungor Katalin^ORCID

Publisher

Informa UK Limited

Reference53 articles.

1. Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study

2. Burden of illness of people with persistent symptoms of schizophrenia: A multinational cross-sectional study

3. Schizophrenia, “just the facts” 4. Clinical features and conceptualization

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses;Journal of Clinical Psychopharmacology;2024-05

2. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan;Schizophrenia Research;2023-02

3. Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia: A comparative study in the Australian context;Australasian Psychiatry;2022-12-07

4. Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: a real-world retrospective cohort study of the United States Veterans Health Administration database;BMC Psychiatry;2022-07-08

5. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study;BMC Psychiatry;2021-12